Dicerna Pharmaceuticals Inc., also headquartered in Cambridge, priced 5.7m shares at $7 each on Dec. 14 for $40m in gross proceeds before overallotments. The cash will fund preclinical and clinical studies, further development of the RNAi company's technology platform, and other expenses. Dicerna closed a $70m offering earlier this year to advance its early-stage pipeline after a setback for its former lead product candidate in 2016. (Also see "Dicerna, Flush With Cash, Is Back To The Drawing Board" - Scrip, 13 June, 2017.) The company also earned an undisclosed upfront fee under a non-alcoholic steatohepatitis (NASH) deal with Boehringer Ingelheim GMBH that's worth up to $201m plus royalties. (Also see "With Dicerna's NASH Asset, Boehringer Found What It Was Looking For" - Scrip, 2 November, 2017.)

Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash

More from Financing

More from Business